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Abstract: Myeloproliferative neoplasms (MPNs) are the most common underlying
prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical
risk factors for MPN-associated SVTs include younger age, female sex, concomitant
hypercoagulable disorders, and the JAK2 V617F mutation. These risk factors are distinct from
those associated with arterial or deep venous thrombosis (DVT) in MPN patients, suggesting
disparate disease mechanisms. The pathophysiology of SVT is thought to derive from local
interactions between activated blood cells and the unique splanchnic endothelial environment.
Other mutations commonly found in MPNs, including CALR and MPL, are rare in MPNassociated SVT. The purpose of this article is to review the clinical and molecular risk factors
for MPN-associated SVT, with particular focus on the possible mechanisms of SVT formation
in MPN patients.

Keywords: Budd-Chiari syndrome, essential thrombocythemia, JAK2, myeloproliferative
neoplasm, polycythemia vera, portal vein thrombosis, primary myelofibrosis, splanchnic vein
thrombosis

Introduction
Myeloproliferative neoplasms (MPNs) are a
group of hematopoietic stem cell disorders characterized by clonal proliferation of myeloid-lineage cells. Classic MPNs include polycythemia
vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid
leukemia (CML) [Tefferi and Vardiman, 2008].
CML is defined by a reciprocal translocation
of chromosomes 9 and 22, resulting in the
Philadelphia chromosome (Ph), and will not be
discussed in this article. The Ph-negative MPNs,
which include PV, ET, and PMF, share many
common clinical and molecular characteristics,
including increased risk of thrombosis and leukemic transformation.
Arterial and venous thromboses are a major cause
of morbidity in Ph-negative MPNs. Venous thrombosis may occur at unusual anatomic sites, such
as splanchnic vein thrombosis (SVT) or cerebral
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sinus thrombosis. SVT refers to thrombosis formation in the portal venous system (portal vein
thrombosis, PVT), hepatic venous system BuddChiari syndrome (BCS), splenic venous system, or
mesenteric venous system. SVTs are rare, with
large epidemiological studies estimating the incidence rate to be 0.7 per 100,000 patients per year
for PVTs and 0.8 per million patients per year for
BCS [Rajani and Almer, 2009; Rajani et al. 2010].
This is significantly lower than the incidence rate
of deep venous thromboses (DVTs), which is estimated to be roughly 100 per 100,000 patients per
year in the United States [White, 2003].
Interestingly, MPNs are the most common underlying prothrombotic disorder found in patients
diagnosed with SVT, in the absence of local inciting factors such as liver cirrhosis or nearby malignancy. In patients with BCS specifically, systemic
factors, such as an underlying MPN, are more
common than local factors [Ageno et al. 2014].
The strong association between SVT and MPN
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has led to recommendations to screen for MPN
when SVT is diagnosed [Smalberg et al. 2012].
The reason for the association between SVT and
MPN is not immediately clear. Age, sex, concomitant hypercoagulable disorders, and the presence
of the JAK2 V617F mutation have all been implicated in the pathogenesis of SVT in MPN.
Improving our understanding of the mechanisms
that predispose to SVT formation is an area of
ongoing research. The purpose of this article is to
review the clinical and molecular risk factors for
MPN-associated SVT, with particular focus on
the possible disease mechanisms of SVT formation in MPN patients. The treatment and management of MPN-associated SVTs have been
discussed extensively in two recently published
reviews [Sekhar et al. 2013; De Stefano et al.
2015], and will not be discussed in this review.
Prevalence of SVT in MPNs
The prevalence of a venous thromboembolism
(VTE) at the time of MPN diagnosis is estimated
to be approximately 11–39% for PV, 8–29% for
ET, and 3–7% for PMF [Barbui et al. 2010; Kreher
et al. 2014]. SVTs represent a fraction of VTE in
MPNs, with an estimated prevalence of 5–10% in
PV patients and 9–13% in ET patients [Anger
et al. 1989; De Stefano et al. 2008]. SVTs occur
even less frequently in PMF patients, with an estimated prevalence rate of 0.6–1% [Anger et al.
1989; Barbui et al. 2010]. PVT is the most common type of SVT (40%), while BCS is the least
common (5%) [De Stefano et al. 2008; Smalberg
et al. 2012]. Conversely, in patients presenting
with SVT, MPNs are the most common underlying prothrombotic disorder. Prevalence rates of
MPN in SVT have ranged from 5–70%, with a
large meta-analysis estimating that 40% of BCS
patients and 30% of PVT patients are subsequently
found to have an underlying MPN [Smalberg et al.
2012; Sekhar et al. 2013]. PV makes up the largest
subgroup in patients with SVT (27%), and PMF
makes up the smallest subgroup (13%) [Smalberg
et al. 2012]. Table 1 summarizes the prevalence
rates of SVTs in MPNs, and vice versa.
Clinical factors associated with SVT in MPN
The proportion of SVT among all VTEs is disproportionately higher in MPN patients compared with the general population, as SVTs make
up an estimated 7.5% of total VTE cases [De
Stefano et al. 2008]. In comparison, the frequency
108

Table 1. (a) SVTs in patients with MPNs compared
with the general population. (b) Prevalence rates of
MPNs in patients found to have an SVT.
(a) Prevalence rates of SVTs.
Within MPNs
PVT
BCS

6100 per 100,000
1200 per 100,000

(b) Prevalence rates of MPNs
Within PVT
40%

Within general
population
3.7 per 100,000
0.14 per 100,000
Within BCS
30%

Sources: De Stefano et al. [2008] - 6100/100,000 PVT
within MPN; Anger et al. [1989] - 1200/100,000 BCS within
MPN; Rajani and Almer [2009] - 0.14 per 100,000 BCS
within general population; Rajani et al. [2010] - 3.7 per
100,000 PVT within general population; Smalberg et al.
[2012] - prevalence rates of MPNs within PVT and BCS.
BCS, Budd-Chiari syndrome; MPN, myeloproliferative
neoplasms; PVT, portal vein thrombosis; SVT, splanchnic
vein thrombosis.

of DVTs and PEs in the general population is 400
times greater than that of SVTs [Deitelzweig et al.
2011]. Interestingly, the risk factors associated
with these unusual thromboses are different from
the risk factors traditionally associated with allcause arterial and venous thrombosis. Figure 1
compares the known clinical risk factors of SVTs
with those of all-cause VTE.
Age and sex. The best established risk factors for
thrombosis in MPN are age >60 years and prior
history of thrombosis [Marchioli et al. 2005;
Kreher et al. 2014; Tefferi and Barbui, 2015].
Analysis of 1638 PV patients collected in the
ECLAP (European Collaboration on Low-dose
Aspirin in Polycythemia vera) trial showed that
only advanced age (>60 years), previous venous
thrombosis (but not arterial thrombosis), and
intermittent claudication demonstrated a statistically significant increased risk of a subsequent
VTE [Landolfi et al. 2007]. In a multivariate analysis of 891 patients with ET, male sex was also
found to be associated with increased venous
thrombosis [Carobbio et al. 2011]. However,
sex was not found to have a significant effect on
VTE in PV patients, nor has this finding been
demonstrated in other epidemiological studies
[Marchioli et al. 2005; Landolfi et al. 2007].
In contrast, MPN patients with SVTs are predominantly younger and female. Lussana and
colleagues evaluated the prevalence of thrombosis
in JAK2-mutated patients younger than 40 years
http://tah.sagepub.com
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factors for SVT [Kiladjian et al. 2008]. In one
study of 40 patients with SVTs, it was found that
38% of patients had an additional risk factor to
MPN, including a hypercoagulable disorder, paroxysmal nocturnal hemoglobinuria (PNH), autoimmune disorder (such as a connective tissue
disease), or ulcerative colitis [De Stefano et al.
2011]. Overall, it has been estimated that multiple concurrent risk factors are present in 10–46%
of BCS patients and 10–64% of PVT patients
[De Stefano et al. 2011].
Figure 1. Venn diagram comparing cited clinical risk
factors for SVTs and all-cause VTEs. Bold indicates
the most validated risk factors.
PVT, portal vein thrombosis; SVT, splanchnic vein
thrombosis; VTE, venous thromboembolism.

of age. In this cohort of 538 patients, venous
thrombosis was significantly higher than arterial
thrombosis (47% versus 34%), and SVTs made
up 79% (26 out of 33) of these VTE cases
[Lussana et al. 2014]. This is in contrast with the
observation that arterial thromboses rates are 2–3
times higher than venous thrombosis rates in the
total MPN population [Barbui et al. 2013]. In
addition, the proportion of SVTs in this younger
population was much higher than in the total
MPN population (79% compared with 7.5%)
[De Stefano et al. 2011; Lussana et al. 2014].
Another study, by Stein and colleagues, compared disease characteristics in a cohort of
younger (age < 45 years) and older (age > 65
years) MPN patients. The investigators found
that although younger patients had a comparable
rate of all-cause thrombosis, SVTs occurred significantly more frequently (13% compared with
2%) in patients younger than 45 years of age
[Stein et al. 2013]. The younger cohort was also
predominantly female, and had a significantly
lower JAK2 allele burden [Stein et al. 2010,
2013]. The observation that SVTs are significantly more frequent in women compared with
men was also noted in the study by Lussana and
colleagues [Lussana et al. 2014]. There are limited data to suggest that other clinical or laboratory risk factors, such as a history of prior
thrombosis or elevated cell counts, increase the
risk of SVTs.
Thrombophilic disorders. Hypercoagulable disorders such as antiphospholipid syndrome, protein
C or S deficiency, factor V Leiden mutation, or
antithrombin deficiency are independent risk
http://tah.sagepub.com

Environmental risk factors. Oral contraceptive
(OCP) use has been implicated as a predisposing
risk factor for VTEs and cerebral sinus thrombosis [Vandenbroucke et al. 1994; Stam, 2005]. It
is unclear of the extent to which OCP use
increases the risk of SVT formation, given the
widespread use of OCPs and the presence of
concomitant hypercoagulable disorders. In one
study examining the etiological factors in BCS,
Smalberg and colleagues identified OCP use in
52% of the 26 female patients. However, these
patients often had an additional prothrombotic
disorder, and the authors did not specify which
combination of etiological factors were present
[Smalberg et al. 2006]. An additional study
examining OCP use and VTE found that nine
OCP-users had developed an SVT, of which two
were JAK2 positive [Grandone et al. 2008]. Neither of these two women had a concomitant
hypercoagulable disorder, although a thrombophilia was present in five of the remaining JAK2negative patients [Grandone et al. 2008]. OCP
use has been shown to increase the risk of VTE
in the presence of an inherited thrombophilia,
and it is possible that SVT risk may be similarly
increased in MPN patients who use OCPs [Vandenbroucke et al. 1994]. This may also partially
explain the observation that females are more
likely to develop an MPN-associated SVT; however, larger epidemiological studies are needed
to potentially establish an association between
MPNs, SVTs, and OCP use.
There are few data to suggest that other environmental exposures play a significant role in
MPN-associated SVT. Some research has suggested that smoking, along with other general
cardiovascular risk factors, increases the rate of
arterial thrombosis, but the data are conflicting
[Falanga and Marchetti, 2014]. There are few
data, however, regarding whether these risk factors apply to venous thrombosis, and specifically SVT.
109
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The JAK2 V617F mutation in MPN-associated
SVT
JAK2 is a tyrosine kinase that initiates intracellular signaling in the JAK/STAT pathway via
binding to receptors for erythropoietin, thrombopoietin, granulocyte colony-stimulating factor,
and granulocyte macrophage colony-stimulating
factor [James, 2008; Oh and Gotlib, 2010]. The
JAK2 V617F mutation causes constitutive activation of the JAK2 kinase, resulting in subsequent
phosphorylation of STAT proteins, ultimately
leading to overproduction of myeloid-lineage
cells [Campbell and Green, 2006; Oh and Gotlib,
2010]. The identification of the JAK2 V617F
mutation in nearly 95% of PV cases and 50–60%
of ET and PMF cases has led to its incorporation
into the diagnostic evaluation of MPNs [Campbell
and Green, 2006]. Current guidelines recommend testing for JAK2 mutations in any patient
suspected to have an MPN [Ageno et al. 2016].
JAK2 mutation in SVT in the absence of overt
MPN
An estimated 40% of BCS patients and 28% of
PVT patients also test positive for the JAK2
V617F mutation [Smalberg et al. 2012]. For this
reason, in any patient presenting with an SVT,
JAK2 testing is recommended as part of the initial work-up for MPN. This has led to the observation that a significant proportion of SVT
patients (15–17%) test positive for JAK2 V617F,
but do not otherwise meet WHO criteria for an
MPN [Smalberg et al. 2012]. Indeed, one study
estimated that testing for JAK2 can identify an
additional 30% of MPN patients who do not
otherwise have overt evidence of disease [De
Stefano et al. 2007]. The most frequently cited
reason for the absence of elevated blood counts
is the presence of portal hypertension and splenomegaly that result from SVT and MPN, which
can lead to sequestration of blood cells as well as
hemodilution, thus ‘masking’ the clinical phenotype of MPN. Investigators have found that
while ‘masked’ patients display lower hemoglobin levels, they also have increased plasma
volumes secondary to splenomegaly or SVT formation [Lamy et al. 1997].
It is also possible that SVT patients with JAK2
V617F, but no overt clinical features of MPN,
may represent a distinct subtype of MPN or an
early phase of the disease. Up to 70% of patients
presenting with SVT do not carry a prior diagnosis
of MPN, and it has been estimated that SVTs
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represent the first thrombotic event in 7.5% of
patients with PV and ET [De Stefano et al. 2008;
Hoekstra et al. 2011]. SVTs may thus occur during an early stage of MPN, prior to the development of the clinical phenotype. For instance, one
meta-analysis found that 21 out of 41 JAK2positive patients without an MPN diagnosis at the
time of SVT presentation subsequently developed
an MPN during follow up [Dentali et al. 2009]. A
more recent study looking at long-term outcomes
of SVT patients also observed that 9 out of 13
JAK2-positive patients were found to have an
MPN after 64 months [Colaizzo et al. 2013].
These findings suggest that in these patients,
SVTs represent an early manifestation of their disease. In Colaizzo and colleagues’ study, six out of
the eight SVT patients who were initially JAK2negative were found to be JAK2-positive with
clinical symptoms of an MPN by 21 months
[Colaizzo et al. 2013]. Such observations suggest
either that a disease process was already in existence before the occurrence of the JAK2 mutation,
or that the initial JAK2 V617F allele burden had
not reached a detectable level by conventional
laboratory testing at the time of SVT diagnosis.
The hypothesis that SVTs are early manifestations
of MPN may partially account for the finding that
MPN-associated SVT patients tend to be younger
with lower JAK2 V617F allele burdens.
The hypothesis that SVT patients represent an
earlier stage of MPN disease has important implications in evaluating the underlying molecular
pathogenesis of MPNs. It has been hypothesized
that blood cancers arise from stepwise genetic
mutations that confer survival and growth advantages to hematopoietic stem cells, eventually
resulting in clonal hematopoiesis and malignancy
[Xie et al. 2014]. While early mutations may allow
clonal expansion, cooperating mutations that
occur later enable development of a hematopoietic cancer. JAK2-positive patients without clinical findings of an MPN may lack these cooperating
mutations that result in blood cell proliferation.
For instance, a significant percentage of MPNassociated mutations, including JAK2 V617F,
have been found in elderly individuals without
overt evidence of an MPN [Genovese et al. 2014;
Xie et al. 2014]. These individuals, however, are
at an increased risk of developing a subsequent
hematologic malignancy and cardiovascular mortality [Jaiswal et al. 2014]. These data suggest that
mutations such as JAK2 V617F can be initiating
events that may ultimately lead to the development of overt malignancy. Similarly, in SVT
http://tah.sagepub.com
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patients who subsequently develop MPNs, it is
possible that the development of thrombosis
reflects pathology related to an initiating clone.
The progression to overt MPN, including elevated cell counts, may only become apparent
upon acquisition of subsequent mutations. These
patients with positive JAK2 mutation status may
thus be considered a ‘pre-malignant’ state, and as
such represent a unique population for studying
the clonal evolution of MPNs.
Prevalence of the JAK2 V617F in MPNassociated SVTs
There is a high prevalence of the JAK2 V617F
mutation found in SVT, and the percentage is
even higher when restricted to patients meeting
MPN criteria with SVT [Patel et al. 2006]. An
estimated 71–100% of patients with overt MPN
and SVT test positive for JAK2 V617F, which is
significantly higher than the prevalence of the
JAK2 mutation in MPN patients with other
VTEs [Austin and Lambert, 2008]. A systematic
review of 24 studies and 3123 patients found that
JAK2 V617F conferred a significantly increased
risk of SVT formation, with an odds ratio of 54
[Dentali et al. 2009]. In addition, while the mean
prevalence of the JAK2 mutation in SVTs was
high (33%, similar to rates reported in the literature), the mean prevalence of JAK2 V617F in
other VTEs was low (0.88–2.57%) [Dentali et al.
2009]. Despite these associations, one study
observed that young females tended to have a
lower JAK2 mutant allele burden, even though
they are at higher risk for SVTs [Stein et al. 2010].
The findings of increased incidence of the JAK2
mutation but lower allele burden may suggest an
‘all or nothing’ effect of the JAK2 mutation,
which is perhaps subsequently modified by additional clinical risk factors such as concomitant
hypercoagulable disorders, as discussed in the
previous section.
JAK2 V617F mutation as a molecular driver of
SVT formation
The majority of SVTs (with the exception of BCS)
are due to local perturbations in the venous system, such as cirrhosis or nearby malignancy. It is
possible that the JAK2 mutation itself may have
local effects on the splanchnic venous system. This
venous system is unique in that blood flow velocity
is much slower, leading to prolonged interactions
between blood and sinusoidal endothelial cells
[Aird, 2007a]. In vitro models have shown that PV
http://tah.sagepub.com

red blood cells demonstrate increased adhesion to
endothelial laminin, and this adhesiveness is particularly increased at low shear rates [Wautier and
Wautier, 2013]. Furthermore, the portal venous
system is exposed to gut-derived inputs, altering its
immunogenicity such that vessels are more vulnerable to activated platelets and states of high viscosity such as increased cell count [Aird, 2007b].
These characteristics may put the splanchnic
venous system at particular risk to perturbations
caused by JAK2 V617F, which affect not only cell
quantity, but cell quality.
The JAK2 mutation has a widespread effect on
the hematologic system. JAK2-mutant megakaryocytes display hypersensitive signaling and
increased mobility and aggregation [Hobbs et al.
2013]. Studies with JAK2 V617F knock-in mice
have demonstrated that megakaryocytes carrying
the JAK2 mutation show greater chemotaxis along
migration assays, as well as increased pro-platelet
formation in response to low-level thrombopoietin
signaling [Hobbs et al. 2013]. JAK2-positive
platelets also display increased in vitro thrombus
formation when exposed to collagen-coated surfaces, although Lamrani and colleagues found
decreased platelet reactivity when tested in a different mouse model [Hobbs et al. 2013; Lamrani
et al. 2014]. However, accelerated platelet aggregation occurred when studied in vivo in artificially
injured blood vessels [Lamrani et al. 2014]. Blood
samples taken from JAK2-positive patients with
MPN also show significantly higher levels of soluble P-selectin, a marker of platelet activation,
compared with JAK2-negative patients with MPN
[Robertson et al. 2007].
Leukocyte activation also contributes to the procoagulant milieu, as studies have shown that
markers of polymorphonuclear activation correlate with markers of hypercoagulability in ET and
PV patients [Falanga et al. 2005]. It is thus
believed that activated leukocytes can cause secretion of pro-coagulant factors, leading to further
platelet activation and aggregation. In JAK2positive patients, the level of both leukocyte and
platelet activation increases with higher JAK2
mutational burden, and an epidemiological study
by Barbui and colleagues found that the highest
incidence of thrombosis was seen in PMF patients
with both leukocytosis and the JAK2 mutation
[Arellano-Rodrigo et al. 2006; Barbui et al. 2013].
Red blood cells also display increased adhesion to
the endothelium in PV patients [Wautier and
Wautier, 2013]. This effect may be mediated by
111
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aberrations in JAK/STAT signaling, as JAK2
V617F can induce phosphorylation of glycoproteins critical for red blood cell adhesion [De
Grandis et al. 2013]. Taken together, these findings suggest that the JAK2 mutation leads to distinct changes in hematopoietic cells that increase
the likelihood of thrombus formation.
The propensity for SVT development in MPN is
also potentially due to differential regulation of
hemostasis in specific vascular beds. Endothelial
cells are integrally involved in regulating thrombosis, and are capable of expressing both proand anticoagulant factors depending on both the
environmental milieu and cell type [Rosenberg
and Aird, 1999]. This is supported by observations that MPNs are associated with specific anatomical locations within the splanchnic venous
system. In MPN patients with BCS, for example,
thrombosis tends to occur in the large, hepatic
veins, while BCS patients with other hypercoagulable disorders tend to have thrombosis involving the inferior vena cava [Valla, 2015]. Signaling
pathways specific to the splanchnic venous system can then cause unique interactions with
mutated blood cells. For instance, in PNH, a
complement-mediated disorder that also presents with increased susceptibility to SVT, the
presence of gut-derived antigens in the splanchnic veins may cause higher local activation of
complement, with subsequent higher rates of
hemolysis and thrombotic activation [van Bijnen
et al. 2012].
Mutant endothelial cells may also contribute to
SVT pathogenesis. Liver endothelial cells isolated
from two BCS patients have been found to carry
the JAK2 mutation [Sozer et al. 2009]. Further
studies have identified the JAK2 mutation in
spleen endothelial cells and circulating endothelial progenitor cells [Teofili et al. 2011; Rosti et al.
2013]. JAK2 V617F-mutated endothelial progenitor cells also displayed increased adherence
to normal mononuclear cells, and were found to
abnormally activate the JAK/STAT pathway
[Teofili et al. 2011]. These findings provide a
framework in which potentially aberrant endothelial cells in the splanchnic venous system interact
with aberrant blood cells, eventually leading to
the formation of SVT. The exact mechanism of
how alterations in the endothelium lead to SVT is
still unclear, and warrants further investigation.
Given the unique environment of the splanchnic
venous system, it is likely that the mechanisms of
SVT formation differ from the mechanisms of
112

arterial and DVT, accounting for the difference in
risk factors.
Other molecular drivers of MPN-associated
SVT
Although the JAK2 mutation plays a significant
role in MPN in SVT, approximately 14–20% of
SVT patients with MPN are JAK2-negative
[Kiladjian et al. 2008; Smalberg et al. 2012]. In
terms of clinical risk factors, JAK2-negative
patients with MPN/SVT are not statistically different from their JAK2-positive counterparts
[Kiladjian et al. 2008]. This leads to the question
of whether there are other mutations that can
account for the prothrombotic state. Specifically,
several mutations with increased incidence in
MPN have been identified, and only recently have
investigators evaluated these mutations in SVT.
CALR mutations
The CALR gene encodes for calreticulin, a multifunctional protein that regulates calcium signaling and protein folding in the endoplasmic
reticulum and cytoplasm [Johnson et al. 2001].
Only recently has a mechanism for CALR-mutant
MPN pathogenesis been proposed. A series of
papers demonstrated that mutated calreticulin is
able to induce MPN phenotypes in mice through
interaction with the thrombopoietin receptor
(MPL) [Araki et al. 2016; Chachoua et al. 2016;
Elf et al. 2016; Marty et al. 2016]. Mutated calreticulin has been shown to bind preferentially to
MPL, resulting in thrombopoietin-independent
activation of MPL with subsequent stimulation of
the JAK/STAT pathway [Araki et al. 2016;
Chachoua et al. 2016; Elf et al. 2016; Marty et al.
2016]. The specificity of mutant calreticulin
interaction with MPL accounts for the findings
that CALR mutations are largely absent in PV,
but found in 30% of all ET and PMF patients,
and 70–80% of JAK2-negative ET or PMF
[Klampfl et al. 2013; Nangalia et al. 2013].
Compared with JAK2, CALR-mutant patients
tend to have increased platelet counts, lower
hemoglobin and white cell counts, as well as
decreased rates of thrombosis, with a more indolent disease course [Nangalia et al. 2013].
How or whether CALR mutations induce SVT
susceptibility is less clear. Despite the relatively
high frequency of CALR mutations in MPNs,
recent studies have failed to find an increased
incidence of CALR mutations in SVT patients.
http://tah.sagepub.com
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CALR mutations have been identified in 0–2% of
SVT, with an estimated total prevalence of
approximately 0.9% of cases [Castro et al. 2015;
Colaizzo et al. 2015; Haslam and Langabeer,
2015; Iurlo et al. 2015; Marzac et al. 2015;
Plompen et al. 2015; Roques et al. 2015; Turon
et al. 2015]. Given its relatively low prevalence,
testing for CALR is not generally recommended
in patients with SVT [Colaizzo et al. 2015].
Furthermore, its rarity suggests that it is not a
major contributor to SVT formation, a fact consistent with the observation that CALR-mutated
patients exhibit decreased rates of thrombosis
overall [Rumi et al. 2014].
MPL mutations
Mutations in the MPL gene are the third most
commonly tested for mutation after JAK2 and
CALR in MPN patients. MPL encodes for the
thrombopoietin receptor, and mutations expectedly cause abnormalities in megakaryocyte and
platelet production. The most common mutations result in an amino acid substitution (either
lysine or leucine) at the 515 position (MPL
W515), are found in approximately 5% of ET/
PMF patients, and are mutually exclusive to
JAK2 and CALR mutations [Pikman et al. 2006;
Rumi et al. 2013]. MPL-mutant patients tend to
be older, with lower cell counts compared with
JAK2 and CALR-positive patients [Beer et al.
2008]. MPL mutations have not been shown to
confer significant prognostic impact, and patients
do not have differing risks of thrombosis or major
hemorrhage [Beer et al. 2008]. However, similar
to CALR, MPL W515 mutations are rare in SVT,
with incidence rates even less than CALR
[Bergamaschi et al. 2008; Kiladjian et al. 2008;
Jadli et al. 2012; Smalberg et al. 2012; Colaizzo
et al. 2015]. This may be related to the overall low
prevalence of MPL in MPNs, but there is no evidence to suggest that MPL-positive patients have
higher rates of SVTs.
The JAK2 46/1 haplotype
The JAK2 46/1 haplotype has recently been
found to be associated with JAK2-positive MPNs,
and it is believed that the JAK2 V617F mutation
arises specifically on the 46/1 allele [Jones et al.
2009]. Its role in SVT formation is controversial,
with some studies showing that the haplotype is
an independent risk factor for SVT development
in JAK2 V617F patients [Colaizzo et al. 2010a;
Smalberg et al. 2011], and some studies showing
http://tah.sagepub.com

only a weak association [Kouroupi et al. 2011]. A
recent meta-analysis of 26 observational studies
evaluated the risk of MPN with the JAK2 haplotype, and found that the haplotype was significantly increased in MPN and SVT patients. In
JAK2-negative patients, however, the haplotype
did not confer an additional risk of SVT [Li et al.
2014]. The increased risk of SVT with the 46/1
haplotype may be due to an interaction of the
haplotype with the JAK2 V617F mutation, rather
than the haplotype itself.
Additional mutations in MPN-associated SVTs
Approximately 10% of MPN patients are ‘triple-negative’ and do not harbor JAK2, CALR,
or MPL mutations [Tefferi et al. 2014].
Additional mutations are found in varying frequencies in PV, PMF, and ET patients,
although they tend not to be mutually exclusive
with JAK2, CALR, MPL mutations, or with
each other. These mutations include TET2,
DNMT3A, EZH2 and ASXL1, and are involved
in DNA methylation and chromatin structuring
[Delhommeau et al. 2009; Grand et al. 2009;
Ernst et al. 2010; Abdel-Wahab et al. 2011].
The specific role of these mutations in driving
MPN disease formation is not fully understood.
As discussed previously, SVT patients may be
an ideal population for investigating the role of
precursor genes and initiating mutations, as
these patients may present at an early stage of
MPN disease evolution. For instance, TET2 is
a tumor suppressor gene which plays a key role
in DNA methylation, and mutations in TET2
have been identified in up to 12% of MPN
patients, including both JAK2-positive and
JAK2-negative MPNs [Delhommeau et al.
2009]. In the hematopoietic stem cells of
patients with both JAK2 and TET2 mutations,
the TET2 mutation could often be found in the
absence of the JAK2 mutation, suggesting the
acquisition of TET2 before JAK2 [Delhommeau
et al. 2009]. In surveying SVT patients, however, only a minority (3/23) of SVT patients
tested positive for TET2, while all were JAK2
positive [Colaizzo et al. 2010b]. A larger study
of 43 BCS patients identified 6 patients with a
deleterious TET2 mutation; however, only 3
were JAK2-negative and none of these 3
patients developed an overt MPN [Westbrook
et al. 2012]. Based on the studies by Colaizzo
and colleagues and Westbrook and colleagues,
the prevalence of TET2 in SVTs is roughly
14%, which is similar to the prevalence rate of
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Table 2. Prevalence of MPN-associated mutations
in SVT and MPN patients. JAK2 makes up the
highest proportion of patients, while CALR and MPL
have very low prevalence rates in SVTs. TET2 is
found at higher prevalence rates but is not mutually
exclusive with JAK2.
SVT patients

MPN patients

JAK2

33%

CALR
MPL
Other
TET2

0.9%
0.7%

95% in PV; 60% in ET
and PMF
30% in ET and PMF
5% in ET and PMF

14%

12%

Sources: MPL- 0.7% in SVT, JAK2- 33% in SVT patientsSmalberg et al. [2012]; CALR- 0.9% in SVT patients- De
Stefano et al. [2015]; MPL- 0.7% in SVT- Bergamaschi
et al. [2008]; CALR- 0.9% in SVT patients- Colaizzo et al.
[2015]; MPL- 0.7% in SVT- Kiladjian et al. [2008]; MPL0.7% in SVT, TET2- 14% in SVT- Jadli et al. [2012]; CALR0.9% in SVT patients- Turon et al. [2015]; TET2- 14% in
SVT- Westbrook et al. [2012]; TET2- 14% in SVT- Colaizzo
et al. [2010b]; 12% in MPN- Delhommeau et al. 2009; 5%
in ET and PMF - Pikman et al. 2006; 95% in PV, 60% in
ET/PMF- Campbell and Green 2006; 30% in ET and PMFKlampf et al. 2013.
ET, essential thrombocythemia; MPN, myeloproliferative
neoplasms; PMF, primary myelofibrosis; PV, polycythemia vera; SVT, splanchnic vein thrombosis.

TET2 in all MPNs [Delhommeau et al. 2009].
While TET2 is found more frequently than
CALR and MPL in SVT, its frequent co-occurrence with JAK2 and lower prevalence rate suggests a limited role in SVT formation. Further
investigations for mutations present in JAK2negative SVT patients are limited. A small
study of 25 cases of JAK2-negative BCS found
no patients with IDH1 or IDH2 mutations [Jadli
et al. 2012].
Table 2 summarizes the prevalence of the most
common MPN-associated mutations in SVTs and
all MPNs. In light of the existing literature, there
seems to be a lack of evidence to suggest that these
other mutations are associated with SVT formation in MPN, despite the finding that 14–20% of
SVT patients with an MPN are JAK2-negative
[Kiladjian et al. 2008; Smalberg et al. 2012]. The
existence of a precursor mutation to JAK2 V617F
critical to SVT pathogenesis has yet to be identified. Additional research examining the clinical
and molecular differences between JAK2-positive
and JAK2-negative patients with SVT is needed
to further elucidate the driving mechanisms of
SVT formation and MPN disease progression.
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Future directions and conclusion
The development of SVTs in MPN is multifactorial and likely includes both environmental and
host genetic factors. Risk factors for the development of SVT in MPN patients include the JAK2
V617F mutation, young age, female sex, and the
presence of concomitant hypercoagulable disorders. Intrinsic characteristics of the splanchnic
venous bed may predispose to thrombotic interactions with atypical blood cells, which are modified by JAK2 V617F or unknown precursor
mutations. Furthermore, the mechanisms that
cause SVT formation likely differ from the mechanisms that cause arterial and DVT, accounting
for the differences in risk factors. There is little
evidence to suggest that other known genetic
alterations implicated in MPN pathogenesis, such
as CALR, MPL, or the JAK2 46/1 haplotype, are
critical for SVT formation. Given that SVT
patients may present at an early stage of MPN,
identifying common mutations may shed light on
the molecular pathogenesis of MPN disease
development and progression.
Research into understanding the occurrence of
SVTs in MPNs also has important implications
for treatment and prognosis. Identifying patients
most at risk for SVT can prevent considerable
morbidity and mortality. Investigation into the
use of JAK2 inhibitors to decrease the risk of
future thrombosis is already under way [Keohane
et al. 2015]. Future directions for research include
better characterization of MPN patients with and
without SVTs, and the development of a database
of such phenotypes. In particular, investigating
differences between JAK2-positive and JAK2negative patients can better clarify the role of
JAK2 V617F in thrombosis formation.
In summary, SVTs occur in a unique subset of
MPN patients, and often present with little overt
MPN disease characteristics. Understanding the
association between SVTs and MPNs can provide insight not just on possible mechanisms of
thrombosis, but also the pathophysiology of disease evolution.
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